Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

This study is testing a cutting-edge treatment where immune cells from a patient's own body are genetically modified in the lab and then given back to fight advanced melanoma or other solid tumours that have not responded to other treatments. The cells are engineered to target a protein called IL13Ralpha2 found on cancer cells. **You may be eligible if...** - You are between 18 and 74 years old - You have stage IIIC or IV melanoma (including brain metastases) or another metastatic solid tumour that has not responded to all available standard treatments - Your tumour tests positive for the IL13Ralpha2 protein - You are in good physical condition (ECOG 0 or 1) - Your blood counts meet required minimums **You may NOT be eligible if...** - Your tumour does not express the IL13Ralpha2 protein - Your cancer has spread to the central nervous system (for non-melanoma cancers) - You are 75 years old or older - Your performance status or blood counts are below required levels Talk to your doctor to see if this trial is right for you.